Analysis of circulating tumor cells (CTCs) in a phase 3 study of docetaxel and prednisone (DP) with or without lenalidomide (LEN) in patients (pts) with castrate-resistant prostate cancer (CRPC): The MAINSAIL trial

被引：0
|
作者：
Vogelzang, N. J. [1 ,2 ]
Petrylak, D. P. [3 ]
Fizazi, K. [4 ]
Sternberg, C. N. [5 ,6 ]
De Wit, R. [7 ]
Liu, K. [8 ]
Waldman, M. [8 ]
Barton, D. [8 ]
Jungnelius, U. [8 ]
Fandi, A. [8 ]
机构：
[1] US Oncol Res, Houston, TX USA
[2] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[3] Yale Canc Ctr, Dept Med, Div Oncol, New Haven, CT USA
[4] Inst Gustave Roussy, Dept Canc Med, Villejuif, France
[5] San Camillo Hosp, Dept Med Oncol, Rome, Italy
[6] Forlanini Hosp, Dept Med Oncol, Rome, Italy
[7] ErasmusMC Canc Inst, Rotterdam, Netherlands
[8] Celgene Corp, Summit, NJ USA
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA23
引用
下载
收藏
页码：S11 / S11
页数：1
相关论文
共 50 条
  • [21] Recovery and characterization of circulating tumor cells (CTCs) in cryopreserved metastatic castrate-resistant prostate cancer (mCRPC) patient samples
    Lu, David
    Harvey, Melissa
    Madan, Ravi
    Heery, Christopher
    Marte, Jennifer
    Beasley, Sharon
    Landers, Mark
    Krupa, Rachel
    Louw, Jessica
    Wahl, Justin
    Bales, Natalee
    Marrinucci, Dena
    Schlom, Jeffrey
    Gulley, James
    Dittamore, Ryan
    CANCER RESEARCH, 2015, 75
  • [22] Phase I trial of a targeted therapy with a psa-based vaccine and ipilimumab in patients (pts) with metastatic castrate-resistant prostate cancer (CRPC)
    Gulley, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 24 - 24
  • [23] SYNERGY: A randomized phase III study comparing firstline docetaxel/prednisone to docetaxel/prednisone plus custirsen in metastatic castrate-resistant prostate cancer (mCRPC).
    Chi, K. N.
    De Bono, J. S.
    Higano, C. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] AUO-Studie AP 60/10Erstlinientherapie beim kastrationsresistenten ProstatakarzinomStudy to evaluate safety and effectiveness of lenalidomide in combination with docetaxel and prednisone for patients with castrate-resistant prostate cancer (Mainsail)
    H. Rexer
    Der Onkologe, 2011, 17 (5): : 435 - 436
  • [25] Phase I trial of metronomic cyclophosphamide (CTX) and lenalidomide (LEN) in patients with castration-resistant prostate cancer (CRPC).
    Wang, Jue
    McGuire, Timothy R.
    Schwarz, James K.
    Meza, Jane L.
    Talmadge, James E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [26] Phase II trial of bevacizumab (B) and oral satraplatin (S) and prednisone in docetaxel pretreated metastatic castrate resistant prostate cancer (CRPC)
    Vaishampayan, U. N.
    Heilbrun, L. K.
    Heath, E. I.
    Smith, D. W.
    Dickow, B.
    Baranowski, K.
    Powell, I.
    Fontana, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [27] Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer
    Heath, Elisabeth
    Heilbrun, Lance
    Mannuel, Heather
    Liu, Glenn
    Lara, Primo
    Monk, J. Paul
    Flaig, Thomas
    Zurita, Amado
    Mack, Philip
    Vaishampayan, Ulka
    Stella, Philip
    Smith, Daryn
    Bolton, Susan
    Hussain, Arif
    Al-Janadi, Anas
    Silbiger, Daniel
    Usman, Muhammad
    Ivy, S. Percy
    ONCOLOGIST, 2019, 24 (09): : 1149 - +
  • [28] A phase I/II study of sunitinib in combination with docetaxel (dcx) and prednisone (pdn) in patients with metastatic castrate-resistant prostate cancer (mCRPC)
    Zurita, A.
    Shore, N. D.
    Kozloff, M. F.
    Ryan, C. W.
    Beer, T. M.
    Maneval, E. Chow
    Chen, I.
    Logothetis, C. J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 287 - 287
  • [29] Circulating tumor cells (CTCs) N-terminal androgen receptor expression to identify patients (pts) with castrate resistant prostate cancer (CRPC) who are more sensitive to chemotherapy.
    Slovin, Susan F.
    Knudsen, Karen E.
    Halabi, Susan
    Carbone, Emily
    Fernandez, Celina
    Chen, Yu
    Autio, Karen A.
    Rathkopf, Dana E.
    Kampel, Lewisj.
    Morris, Michael J.
    Arauz, Gabrielle
    Graf, Ryon P.
    Kelvin, James
    Dittamore, Ryan Vance
    De Leeuw, Renee
    Sullivan, Amanda
    Tse, Kin
    Molina, Ana M.
    Scher, Howard I.
    Kelly, William Kevin
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial
    Petrylak, Daniel P.
    Vogelzang, Nicholas J.
    Budnik, Nikolay
    Wiechno, Pawel Jan
    Sternberg, Cora N.
    Doner, Kevin
    Bellmunt, Joaquim
    Burke, John M.
    de Olza, Maria Ochoa
    Choudhury, Ananya
    Gschwend, Juergen E.
    Kopyltsov, Evgeny
    Flechon, Aude
    Van As, Nicolas
    Houede, Nadine
    Barton, Debora
    Fandi, Abderrahim
    Jungnelius, Ulf
    Li, Shaoyi
    de Wit, Ronald
    Fizazi, Karim
    LANCET ONCOLOGY, 2015, 16 (04): : 417 - 425
12345